Introduction: Deep vein thrombosis (DVT) is a potentially life-threatening complication in patients with cancer. Among cancers, lymphomas have a particularly elevated risk of thromboembolism due to both disease-related factors and chemotherapy. Although the association between lymphoma and thrombosis is established, the impact of lymphoma on inpatient outcomes among patients with DVT remains deficient, especially at a national level. Using seven years of data from the National Inpatient Sample (NIS), the largest all-payer inpatient database in the United States, this study aims to examine epidemiology, clinical outcomes, healthcare costs, and characterize the burden for hospitalized DVT patients with and without a diagnosis of lymphoma.

Methods: Hospitalizations for DVT and Lymphoma were identified using ICD-10-CM codes from the NIS for years 2016-2022, and integrated sampling weights were applied to generate nationally representative estimates. The primary outcomes analyzed using logistic and linear regression were in-hospital mortality, average length of stay (LOS), and total hospital charges, while secondary outcomes included in-hospital complications. Outcomes were adjusted for demographics and comorbidities. Results were reported as adjusted odds ratios (aOR), and a p<0.05 was considered statistically significant. Statistical analysis was performed by the STATA (version 17).

Results: In our sample of 2,929,708 hospitalizations for deep vein thrombosis (DVT) from 2016 to 2022, 52,035 (1.8%) involved patients who also carried a diagnosis of lymphoma. Compared with patients without lymphoma, this subgroup was older on average (mean age 65.4 vs. 64.5 years, p<0.0001), more often male (57.9% vs. 51.8%, p<0.0001), and more frequently White (72.2% vs. 67.6%), with fewer Black patients (10.9% vs. 18.8%, p<0.0001). The Charlson Comorbidity Index (CCI) suggested significant comorbidity burden in lymphoma subgroup (45.9% vs. 32.4% with a CCI ≥ 4). However, individual comorbidities were less frequent in the lymphoma group: diabetes (22.2% vs. 28.4%), chronic kidney disease (15.6% vs. 18.4%), and obesity (12.6% vs. 20.8%), all with p<0.0001. Patients with lymphoma had higher likelihood of developing sepsis (21.4% vs. 18.0%, p<0.0001), disseminated intravascular coagulation (1.3% vs. 0.8%, p<0.0001), and acute kidney injury (31.1% vs. 29.3%, p=0.0002). Pulmonary embolism was less common in the lymphoma group (18.8% vs. 31.1%, p<0.0001). Bleeding events and adverse effects of anticoagulants were less frequent in lymphoma patients. In-hospital mortality was significantly higher in the lymphoma group (10.0% vs. 6.8%), with an aOR of 1.21 (95% CI: 1.13–1.30, p<0.0001). Furthermore, mean LOS was longer in the lymphoma subgroup (11.8 vs. 10.0 days). Adjusted analysis demonstrated an additional 1.16 days in lymphoma patients (95% CI: 0.84–1.48, p<0.0001). Lastly, Hospitalization costs were also higher in the lymphoma group (mean $171,602 vs. $139,171), which rose to $19,804 higher charges after adjustment (95% CI: $12,206–$27,403, p<0.0001).

Conclusions: Over seven years of NIS data, we identified nearly 3,000,000 DVT admissions, 1.8% of which involved lymphoma. Classic comorbidities such as diabetes and CKD were both less common in these patients, yet they faced a 21% higher chance of dying in the hospital, stayed about two days longer, and incurred nearly $20,000 more in charges. They were also less prone to pulmonary embolism but far more likely to develop sepsis, DIC, and acute kidney injury. This pattern reveals a heavy inpatient burden for DVT in lymphoma and underscores the need to discover the underlying mechanisms behind these gaps, and to translate that knowledge into personalized care plans.

This content is only available as a PDF.
2025
Sign in via your Institution